Olmesartan Medoxomil | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Olmesartan Medoxomil
Health Canada Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

Contact Supplier

IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Contact Supplier

medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

Contact Supplier

Coral

Contact Supplier

ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

Contact Supplier

Olmesartan Medoxomil

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

148 API Suppliers, 45 USDMF, 42 CEP/COS, 18 JDMF, 28 EU WC, 43 KDMF, 26 NDC API, 58 Listed Suppliers, $ API Reference Price

148 API Suppliers
45 USDMF
42 CEP/COS
18 JDMF
28 EU WC
43 KDMF
26 NDC API
58 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

38 Drugs in Development

38 Drugs in Development

INTERMEDIATES

49 Intermediate Suppliers

49 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

765 FDF Dossiers, 214 FDA Orange Book, 282 Europe, 51 Canada, 40 Australia, 178 Listed Dossiers

765 FDF Dossiers
214 FDA Orange Book
282 Europe
51 Canada
40 Australia
178 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 20MG, TABLET;ORAL - 40MG, TABLET;ORAL - 5MG, TABLET;ORAL - 12.5MG;20MG, TABLET;ORAL - 12.5MG;40MG, TABLET;ORAL - 25MG;40MG, TABLET;ORAL - EQ 10MG BASE;20MG, TABLET;ORAL - EQ 10MG BASE;40MG, TABLET;ORAL - EQ 5MG BASE;20MG, TABLET;ORAL - EQ 5MG BASE;40MG

TABLET;ORAL - 20MG
TABLET;ORAL - 40MG
TABLET;ORAL - 5MG
TABLET;ORAL - 12.5MG;20MG
TABLET;ORAL - 12.5MG;40MG
TABLET;ORAL - 25MG;40MG
TABLET;ORAL - EQ 10MG BASE;20MG
TABLET;ORAL - EQ 10MG BASE;40MG
TABLET;ORAL - EQ 5MG BASE;20MG
TABLET;ORAL - EQ 5MG BASE;40MG

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 4 SPI Pharma, 15 DKSH, 3 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 2 Kirsch Pharma, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 1 Avesta Pharma, 21 BASF, 3 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Esteem Industries, 1 Finar, 7 Gangwal Chemicals, 5 Ideal Cures, 4 Ingredion Pharma Solutions, 26 Kerry, 4 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 21 Roquette, 9 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

59 Fillers, Diluents & Binders, 51 Coating Systems & Additives, 32 Thickeners and Stabilizers, 30 Disintegrants & Superdisintegrants, 29 Direct Compression, 28 Granulation, 24 Controlled & Modified Release, 24 Lubricants & Glidants, 20 Topical, 16 Solubilizers, 15 Film Formers & Plasticizers, 12 Co-Processed Excipients, 10 Rheology Modifiers, 9 Parenteral, 9 Taste Masking, 8 Chewable & Orodispersible Aids, 8 Emulsifying Agents, 6 Surfactant & Foaming Agents, 6 API Stability Enhancers, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules

59 Fillers, Diluents & Binders
51 Coating Systems & Additives
32 Thickeners and Stabilizers
30 Disintegrants & Superdisintegrants
29 Direct Compression
28 Granulation
24 Controlled & Modified Release
24 Lubricants & Glidants
20 Topical
16 Solubilizers
15 Film Formers & Plasticizers
12 Co-Processed Excipients
10 Rheology Modifiers
9 Parenteral
9 Taste Masking
8 Chewable & Orodispersible Aids
8 Emulsifying Agents
6 Surfactant & Foaming Agents
6 API Stability Enhancers
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules

DIGITAL CONTENT

94 News #PharmaBuzz

94 News #PharmaBuzz

GLOBAL SALES INFORMATION

35 US Medicaid Prescriptions, 268 Regulatory FDF Prices, 16 Annual Reports

35 US Medicaid Prescriptions
268 Regulatory FDF Prices
16 Annual Reports

MARKET PLACE

31 APIs, 7 FDF Dossiers, 1 Intermediates

31 APIs
7 FDF Dossiers
1 Intermediates

PATENTS & EXCLUSIVITIES

6 Health Canada Patents

6 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 4 JP, 15 Others

2 EDQM
4 JP
15 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 681 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 5Merck Canada Inc.

02 1Schering-Plough Canada Inc.

filter Patent Reset all filters

6 All

01 62061607

filter Product Reset all filters

6 All

01 3Olmesartan Medoxomil

02 3Olmesartan medoxomil | hydrochlorothiazide

filter Dosage Reset all filters

6 All

01 6Tablet

filter Exp Date Reset all filters

6 All

01 62012-02-20

Product Main Page

01

Schering-Plough Canada Inc.

Olmesartan medoxomil, hydrochlorothiazide

Formnext Forum

Not Confirmed

Schering-Plough Canada Inc.

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Olmesartan medoxomil, hydrochlorothiazide

Brand Name : OLMETEC PLUS

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 40 mg / 12.5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Merck Canada Inc.

Olmesartan Medoxomil

Formnext Forum

Not Confirmed

Merck Canada Inc.

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1991-01-19

Olmesartan Medoxomil

Brand Name : OLMETEC

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2012-02-20

Date Granted : 1991-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Merck Canada Inc.

Olmesartan Medoxomil

Formnext Forum

Not Confirmed

Merck Canada Inc.

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Olmesartan Medoxomil

Brand Name : OLMETEC

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 20 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Merck Canada Inc.

Olmesartan Medoxomil

Formnext Forum

Not Confirmed

Merck Canada Inc.

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Olmesartan Medoxomil

Brand Name : OLMETEC

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 40 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Merck Canada Inc.

Olmesartan medoxomil, hydrochlorothiazide

Formnext Forum

Not Confirmed

Merck Canada Inc.

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Olmesartan medoxomil, hydrochlorothiazide

Brand Name : OLMETEC PLUS

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 20 mg / 12.5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Merck Canada Inc.

Olmesartan medoxomil, hydrochlorothiazide

Formnext Forum

Not Confirmed

Merck Canada Inc.

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Olmesartan medoxomil, hydrochlorothiazide

Brand Name : OLMETEC PLUS

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 40 mg / 25 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : oral

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!